More recently, in patients with unresectable/metastatic melanoma (stage IIIb-IV) treated with anti-PD-1 therapy in the first-line setting, a high baseline NLR was associated with a worse prognosis and higher LDH levels. This evidence concerns the gene PDCD1 and metastatic melanoma.